METabolic EXplorer consults its shareholders concerning the principle of a possible sale of its L-Methionine technology

METabolic EXplorer: Financial results, second quarter 2016
29 July 2016
METabolic EXplorer and Technip sign agreement to evaluate combined PDO/PTT technology
23 August 2016
Show all

METabolic EXplorer consults its shareholders concerning the principle of a possible sale of its L-Methionine technology

Download the press release

Clermont-Ferrand, 1st August 2016 – METabolic EXplorer, a biological chemistry company that specialises in developing manufacturing bioprocesses for bio-based compounds used in a wide range of everyday products, including textile fibres, animal feed supplements and resins, consults its shareholders concerning the principle of a possible sale of its L-Methionine technology.

Since the end of 2015, the Board of Directors of METEX has met several times to review various scenarios for valorizing the company’s most mature assets.

As part of this process, it set up a financial scenarios assessment committee within the Board on
18 February 2016.

On this committee’s recommendation, the Board of Directors decided at end-July 2016 that the sale of the L-Methionine technology was one of the options that would be in the company’s interest.

The Board of Directors therefore decides to consult its shareholders concerning the principle of such a sale, in accordance with Recommendation 2015-05 of the Autorité des Marchés Financiers, as well as concerning the possibility of financial incentives for the company’s personnel in such a possible transaction.

A General Meeting of METEX shareholders will thus be convened on 15 September 2016. The Board of Directors’ report on the resolutions submitted for shareholders’ approval will be posted on the company’s website on 25 August 2016.

 Date of the General Meeting:
15 September 2016, 10 a.m., on the first notification
29 September 2016, 10 a.m., on the second notification

Place: Espace Affaire, Clermont-Ferrand Auvergne International Airport, 63510 Aulnat

About METabolic EXplorer

METabolic EXplorer is a biological chemistry company founded in 1999. Its aim is to harness its biotechnological innovations to contribute to the alternative production of consumer goods in respect of the environment and in response to the new social expectations of consumers.

Based on the tried and tested principle of industrial fermentation, METabolic EXplorer’s solutions replace today’s petrochemical processes with the use of a wide range of plant-based raw materials. By optimizing the metabolic yield of non-pathogenic bacteria in a contained, controlled environment, the company facilitates the production of chemical compounds used in a wide range of everyday goods (textile fibres, plastics, resins, solvents or feed supplements for animal nutrition and health).

METabolic EXplorer is currently focusing its alternative processes on the production of three compounds that together have an estimated, annual, end-market value of €7 billion. The company’s strategy will be implemented through industrial partnerships in the shape of licenses and joint ventures, as well as own-account production units.

METabolic EXplorer, based in Clermont-Ferrand, France, is listed on Euronext in Paris (Compartment C, METEX) and is part of the CAC Small index.


Get free financial information on METabolic EXplorer by registering with: or

 Media and individual shareholder relations
ATTITUDE Corporate
Eric de Lambert
Tél.: +33 (0)6 2529 0658

Investor and analyst relations
ACTUS finance & communication
Jérôme Fabreguettes-Leib
Tél. : +33 (0)1 5367 3678


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.